A- A A+

APA: Pharmacological Treatment of Patients with Alcohol Use Disorder

The Practice Guideline for the Pharmacological Treatment of Patients with Alcohol Use Disorder was approved by the APA Assembly in May and by the APA Board of Trustees July 2017. (APA – American Psychiatric Association, Clinical Practice Guidelines, 05.02.2018)

https://www.psychiatry.org/psychiatrists/practice/clinical-practice-guidelines

Handbuch Substitutionsbehandlung in Oberösterreich

Sachverständigenkommission zur regionalen Koordination der Substitutionsbehandlung

Linz, 2016

Version 2.0

https://www.land-oberoesterreich.gv.at/Mediendateien/Formulare/DokumenteAbt_San/Ges_Handbuch_Substitutionsbehandlung.pdf

Guidelines on the management of co-occurring alcohol and other drug and mental health conditions in alcohol and other drug treatment settings

NHMRC Centre of Research Excellence in Mental Health and Substance Use, National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia; 2016

https://comorbidity.edu.au/sites/default/files/National%20Comorbidity%20Guidelines%202nd%20edition.pdf

Deutsch-Österreichische Leitlinien zur Postexpositionellen Prophylaxe der HIV-Infektion

Federführung: Deutsche AIDS-Gesellschaft (DAIG)

unter Beteiligung der folgenden Fachgesellschaften:

•Österreichische AIDS-Gesellschaft (ÖAIG)

•Deutschen AIDS-Hilfe (DAH)

•Bundeszentrale für gesundheitliche Aufklärung (BZgA)

•Nationales Referenzzentrum für Retroviren, Universitätsklinikum Frankfurt

•Robert Koch-Institut (RKI)

•Kompetenznetz HIV/AIDS

Annahme der aktuellen Version durch Mitgliederbeschluss der Deutschen AIDS Gesellschaft (DAIG) am 13.06.2013

https://www.aidshilfe.de/sites/default/files/documents/Deutsch-Osterreichische%20Leitlinien%20zur%20Postexpositionellen%20Prophylaxe%20der%20HIV-Infektion.pdf

UK. Guidance: Drug misuse and dependence: UK guidelines on clinical management - How clinicians should treat people with drug misuse and drug dependence problems.

Published 14 July 2017, Last updated 15 December 2017

Government of UK, Department of Health

This 2017 version offers new guidelines on:

prison-based treatment

new psychoactive substances and club drugs

mental health co-morbidity

misuse of prescribed and over-the-counter medicines

stopping smoking

preventing drug-related deaths, including naloxone provision

https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/668611/clinical_guidelines_2017.pdf

Neufassung des Genfer Gelöbnisses liegt auf Deutsch vor

Berlin – Die überarbeitete Fassung des Genfer Gelöbnisses liegt nun auch in deutscher Übersetzung vor. Darauf hat die Bundesärztekammer (BÄK) hingewiesen. Die überarbeitete Version wurde zwischen den deutschsprachigen Mitgliedsverbänden und den Ethikexperten des Weltärztebundes (WMA) abgestimmt. Der WMA hatte im Oktober 2017 eine modernisierte Fassung des hippokratischen Eids für Ärzte verabschiedet. (aerzteblatt.de, 04.12.2017)

https://www.aerzteblatt.de/nachrichten/85808/Neufassung-des-Genfer-Geloebnisses-liegt-auf-Deutsch-vor

Responding to children and adolescents who have been sexually abused - WHO clinical guidelines

Number of pages: 73
Publication date: 2017
Languages: English
ISBN: 978-92-4-155014-7

Sexual abuse of children and adolescents is a gross violation of their rights and a global public health problem. It adversely affects the health of children and adolescents. Health care providers are in a unique position to provide an empathetic response to children and adolescents who have been sexually abused. Such a response can go a long way in helping survivors recover from the trauma of sexual abuse.

WHO has published new clinical guidelines Responding to children and adolescents who have been sexually abused aimed at helping front-line health workers, primarily from low resource settings, in providing evidence-based, quality, trauma-informed care to survivors. The guidelines emphasize the importance of promoting safety, offering choices and respecting the wishes and autonomy of children and adolescents. They cover recommendations for post-rape care and mental health; and approaches to minimizing distress in the process of taking medical history, conducting examination and documenting findings.

http://www.who.int/reproductivehealth/publications/violence/clinical-response-csa/en

Guidance for commissioners, providers and clinicians on the roles of nurses in alcohol and drug treatment in England. (PHE – Public Health England publications gateway number 2017349, UK, 20.10.2017)

https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/652963/Role_of_nurses_in_alcohol_and_drug_services.pdf

Kanada. Guidance for Injectable Opioid Agonist Treatment for Opioid Use Disorder

British Columbia, Ministry of Health and British Columbia Centre on Substance Abuse, 2017

http://www.bccsu.ca/wp-content/uploads/2017/10/BC-iOAT-Guidelines-10.2017.pdf

WHO. Guidelines for identification and management of substance use and substance use disorders in pregnancy

WHO - World Health Organization, 2014, ISBN: 9789241548731

http://www.who.int/substance_abuse/publications/pregnancy_guidelines/en/

Monthly take-home methadone maintenance regime for elderly opium-dependent users in Singapore.

Guo S, Winslow M, Manning V, Thane KK.

Ann Acad Med Singapore. 2010 Jun;39(6):429-34.

http://www.annals.edu.sg/pdf/39VolNo6Jun2010/V39N6p429.pdf

Responsible, Safe, and Effective Prescription of Opioids for Chronic Non-Cancer Pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines.

Manchikanti L, Kaye AM, Knezevic NN, McAnally H, Slavin K, Trescot AM, Blank S, Pampati V, Abdi S, Grider JS, Kaye AD, Manchikanti KN, Cordner H, Gharibo CG, Harned ME, Albers SL, Atluri S, Aydin SM, Bakshi S, Barkin RL, Benyamin RM, Boswell MV, Buenaventura RM, Calodney AK, Cedeno DL, Datta S, Deer TR, Fellows B, Galan V, Grami V, Hansen H, Helm Ii S, Justiz R, Koyyalagunta D, Malla Y, Navani A, Nouri KH, Pasupuleti R, Sehgal N, Silverman SM, Simopoulos TT, Singh V, Solanki DR, Staats PS, Vallejo R, Wargo BW, Watanabe A, Hirsch JA.

Pain Physician. 2017 Feb;20(2S):S3-S92.

http://www.painphysicianjournal.com/current/pdf?article=NDIwMg%3D%3D&journal=103

The American College of Obstetricians and Gynecologists: Opioid Use and Opioid Use Disorder in Pregnancy

Committee Opinion No. 711 Summary

Obstetrics & Gynecology: August 2017 - Volume 130 - Issue 2 - p 488–489

doi: 10.1097/AOG.0000000000002229

http://journals.lww.com/greenjournal/Fulltext/2017/08000/Committee_Opinion_No__711_Summary___Opioid_Use_and.50.aspx

UK. Drug misuse and dependence: UK guidelines on clinical management - How clinicians should treat people with drug misuse and drug dependence problems.

Often called the Orange Book, this is guidance for clinicians treating people with drug problems.

This 2017 version offers new guidelines on:

- prison-based treatment

- new psychoactive substances and club drugs

- mental health co-morbidity

- misuse of prescribed and over-the-counter medicines

- stopping smoking

- preventing drug-related deaths, including naloxone provision

The new guidelines also have a stronger emphasis on recovery and a holistic approach to the interventions that can support recovery. (Clinical Guidelines on Drug Misuse and Dependence Update 2017, Independent Expert Working Group (2017) Drug misuse and dependence: UK guidelines on clinical management. London: Department of Health. Department of Health, Drug misuse and dependency, 14.07.2017)

https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/628634/clinical_guidelines_2017.pdf

Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring. (National Academy of Sciences, USA.

https://www.nap.edu/catalog/24781/pain-management-and-the-opioid-epidemic-balancing-societal-and-individual

Kanada. A Guideline for the Clinical Management of Opioid Use Disorder, British Columbia 2017

Hrsg.: British Columbia Ministry of Health and British Columbia Centre on Substance Abuse

http://www.bccsu.ca/wp-content/uploads/2017/02/BC-OUD-Guidelines_FINAL.pdf

Österreich. LEITLINIE – QUALITÄTSSTANDARDS FÜR DIE OPIOID-SUBSTITUTIONSTHERAPIE

HERAUSGEBER: Österreichische Gesellschaft für arzneimittelgestützte Behandlung von Suchtkrankheit (ÖGABS); Österreichische Gesellschaft für Allgemein- und Familienmedizin (ÖGAM), Österreichische Gesellschaft für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie (ÖGKJP), Österreichische Gesellschaft für Psychiatrie und Psychotherapie (ÖGPP)

Diese Leitlinie entstand auf Basis des Projektes „Erarbeitung von Qualitätsstandards für die Opioid-Substitutionstherapie“ unter der Ägide des im Bundesministerium für Gesundheit und Frauen (BMGF) eingerichteten „Ausschusses für Qualität und Sicherheit in der Substitutionsbehandlung“.

1.Auflage, 2017

http://www.bmgf.gv.at/cms/home/attachments/9/4/7/CH1028/CMS1492759717914/leitlinie-qualitaetsstandards_opioid-substitutionstherapie.pdf

Guidelines for Addressing Benzodiazepine Use in Opioid Treatment Programs (OTPs)

AATOD is releasing newly developed Benzodiazepine Guidelines for OTPs. They have been extensively vetted among treatment providers, state officials, physicians and other interested parties. AATODs' Medications Committeee (Dr. George Stavros, MD (Chair), Janice Kauffman, RN, MPH, Brian McCarroll, MS, DO, Shirley Linzy, DNP, MS, and Ken Stoller, MD) developed these guidelines over the course of the past year. I am particularly grateful to Jan Kauffman for organizing the development of these guidelines with the members of the Medications Committee.

The clinical issue of benzodiazepine use and abuse by patients in our treatment programs has been extremely challenging. It is our collective hope that these guidelines will serve as a resource to our membership and the field. The AATOD Board of Directors and I would be interested in receiving your feedback. (AATOD - American Association for the Treatment of Opioid Dependence (AATOD), April 2107)

http://www.aatod.org/guidelines-for-addressing-benzodiazepine-use-in-opioid-treatment-programs-otps/#_edn2

Een praktische handreiking voor artsen, verpleegkundig specialisten en physician assistents

Deze handreiking bevat een format dat door artsen, verpleegkundig specialisten en physician assistants gebruikt kan worden als basis voor het somatisch onderzoek bij patiënten met een opiaatverslaving. Het SOO werd ontwikkeld door het Netwerk Infectieziekten & Harm Reduction. (2016, Trimbos-instituut, Utrecht, Niederlande)

https://assets.trimbos.nl/docs/62534c41-09eb-47db-9aea-a8c014557965.pdf

UK. Coexisting severe mental illness and substance misuse: community health and social care services

NICE - National Institute for Health and Care Excellence, Published date: November 2016

https://www.nice.org.uk/guidance/ng58

UK. Coexisting severe mental illness (psychosis) and substance misuse: assessment and management in healthcare settings

NICE guideline [NG58], NICE - National Institute for Health and Care Excellence, Clinical guideline [CG120] Published date: March 2011

https://www.nice.org.uk/guidance/cg120

World Health Organization

Number of pages: 174

Publication date: 2016

Languages: English

ISBN: 978 92 4 154979 0

This is the second version (2016) of the mhGAP Intervention Guide (mhGAP-IG) for mental, neurological and substance use (MNS) disorders in non-specialist health settings. It is for use by doctors, nurses, other health workers as well as health planners and managers. The Intervention Guide presents the integrated management of priority MNS conditions using algorithms for clinical decision making.

This update of the 2010 edition is based on new evidence as well as extensive feedback and recommendations from experts in all WHO regions who have used mhGAP-IG Version 1.0. The key updates include: content update in various sections based on new evidence; design changes for enhanced usability; a streamlined and simplified clinical assessment that includes an algorithm for follow-up; inclusion of two new modules - Essential Care and Practice that includes general guidelines and Implementation module to support the proposed interventions by necessary infrastructure and resources; and, revised modules for Psychoses, Child and Adolescent Mental and Behavioural Disorders and Disorders due to Substance Use.

The mhGAP-IG Version 2.0 is a valuable tool to scale up services for people with MNS conditions and their families.

http://www.who.int/mental_health/mhgap/mhGAP_intervention_guide_02/en/

RCGP Substance Misuse & Associated Health (SMAH) formerly known as RCGP Substance Misuse Unit (SMU), RCGP Sex, Drugs and HIV Group (SDHIVG), Substance Misuse Management in General Practice ( SMMGP), The Alliance, 1st Edition 2011, For review 2013

http://www.smmgp.org.uk/download/guidance/guidance004.pdf

Technology appraisal guidance (TA114)

NICE - National Institute for Health and Care Excellence, 24.01.2007

https://www.nice.org.uk/guidance/ta114

Health Canada, 1992; ISBN: 0-662-59256-5; Cat. No.: H42-2/57-1992

http://www.hc-sc.gc.ca/hc-ps/pubs/precurs/opi-treat-trait/index-eng.php

SAMHSA - Substance Abuse and Mental Health Services Administration.

HHS Publication No. (SMA) PEP15-FEDGUIDEOTP. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2015.

http://store.samhsa.gov/shin/content/PEP15-FEDGUIDEOTP/PEP15-FEDGUIDEOTP.pdf

The American Society of Addiction Medicine (ASAM) has created two resources so physicians treating addiction can access the ASAM National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use anytime, anywhere. The National Practice Guideline Pocket Guide and App will allow physicians to consult the only document to include all FDA-approved medications used to treat addiction in both hard-copy and digital form ASAM, USA, 2016

http://www.asam.org/quality-practice/guidelines-and-consensus-documents/npg/pocket-guide-and-app